{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:06:28Z","timestamp":1789693588010,"version":"4.0.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["374817"],"award-info":[{"award-number":["374817"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","award":["1039354"],"award-info":[{"award-number":["1039354"]}],"id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["938854"],"award-info":[{"award-number":["938854"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The cytokine-signaling inhibitor ruxolitinib causes disease flares of chronic lymphocytic leukemia (CLL). This tumor-promoting activity correlates with its ability to inhibit interleukin (IL)-10 production by CLL B cells that have been activated with IL-2 and the Toll-like receptor 7 (TLR7) agonist resiquimod (called 2S cells) in vitro. In TLR-activated normal human B cells, IL-10 production is regulated by cholesterol biosynthesis and can be inhibited by statins. The goal of this study was to determine if statins affect IL-10 production by 2S cells. Lipophilic statins decreased IL-10 production from 2S CLL cells by inhibiting activation of MYC along with secondary signaling events that amplify and maintain IL10 transcription. IL-10 production was restored when the prenylation defect imposed by statins was corrected by adding geranylgeranyl pyrophosphate. CLL cells activated by ruxolitinib in vivo were enriched with genes associated with prenylation inhibition in TLR-activated human B cells in vitro. These findings suggest IL-10 production by 2S-activated CLL cells is regulated by cholesterol biosynthesis in part through geranylgeranyl pyrophosphate production and substrate prenylation. If IL-10 production in the 2S model constitutes a surrogate test for drug responses in vivo, realization of the potential clinical benefits of statins in CLL may require coadministration of other agents.<\/jats:p>","DOI":"10.1093\/jimmun\/vkaf103","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:48:27Z","timestamp":1748893707000},"page":"2453-2463","source":"Crossref","is-referenced-by-count":3,"title":["Effect of statins on IL-10 signaling and production by chronic lymphocytic leukemia cells"],"prefix":"10.1093","volume":"214","author":[{"given":"Guizhi","family":"Wang","sequence":"first","affiliation":[{"name":"Biology Platform, Sunnybrook Research Institute , Toronto, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina YuXuan","family":"Luo","sequence":"additional","affiliation":[{"name":"Biology Platform, Sunnybrook Research Institute , Toronto, Ontario,","place":["Canada"]},{"name":"Department of Immunology, University of Toronto , Toronto, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Shi","sequence":"additional","affiliation":[{"name":"Biology Platform, Sunnybrook Research Institute , Toronto, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6636-2421","authenticated-orcid":false,"given":"Aditya","family":"Surya","sequence":"additional","affiliation":[{"name":"Biology Platform, Sunnybrook Research Institute , Toronto, Ontario,","place":["Canada"]},{"name":"Department of Medical Biophysics, University of Toronto , Toronto, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haggag S","family":"Zein","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dalhousie University , Halifax, Nova Scotia,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D","family":"Fairn","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dalhousie University , Halifax, Nova Scotia,","place":["Canada"]},{"name":"Department of Biochemistry and Molecular Biology, Dalhousie University , Halifax, Nova Scotia,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Spaner","sequence":"additional","affiliation":[{"name":"Biology Platform, Sunnybrook Research Institute , Toronto, Ontario,","place":["Canada"]},{"name":"Department of Immunology, University of Toronto , Toronto, Ontario,","place":["Canada"]},{"name":"Department of Medical Biophysics, University of Toronto , Toronto, Ontario,","place":["Canada"]},{"name":"Department of Hematology, Odette Cancer Center , Toronto, Ontario,","place":["Canada"]},{"name":"Department of Medicine, University of Toronto , Toronto, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"2025093003513335900_vkaf103-B1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of CLL: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"2025093003513335900_vkaf103-B2","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2011-03-342436","article-title":"Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia","volume":"118","author":"Yan","year":"2011","journal-title":"Blood"},{"key":"2025093003513335900_vkaf103-B3","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3324\/haematol.2015.135418","article-title":"Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial","volume":"101","author":"Spaner","year":"2016","journal-title":"Haematologica"},{"key":"2025093003513335900_vkaf103-B4","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: Much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"2025093003513335900_vkaf103-B5","doi-asserted-by":"crossref","first-page":"e20190418","DOI":"10.1084\/jem.20190418","article-title":"Biology and therapeutic potential of interleukin-10","volume":"217","author":"Saraiva","year":"2020","journal-title":"J Exp Med"},{"key":"2025093003513335900_vkaf103-B6","doi-asserted-by":"crossref","first-page":"1043694","DOI":"10.3389\/fonc.2023.1043694","article-title":"Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo","volume":"13","author":"Spaner","year":"2023","journal-title":"Front Oncol"},{"key":"2025093003513335900_vkaf103-B7","doi-asserted-by":"crossref","first-page":"8789","DOI":"10.1002\/cam4.4378","article-title":"Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial","volume":"10","author":"Spaner","year":"2021","journal-title":"Cancer Med"},{"key":"2025093003513335900_vkaf103-B8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/cam4.2042","article-title":"Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial","volume":"8","author":"Spaner","year":"2019","journal-title":"Cancer Med"},{"key":"2025093003513335900_vkaf103-B9","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1158\/1078-0432.CCR-20-1967","article-title":"Statins as anticancer agents in the era of precision medicine","volume":"26","author":"Longo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025093003513335900_vkaf103-B10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/10428194.2015.1088651","article-title":"A link between hypercholesterolemia and chronic lymphocytic leukemia","volume":"57","author":"Chow","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2025093003513335900_vkaf103-B11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ebiom.2016.11.033","article-title":"Low density lipoproteins amplify cytokine-signaling in chronic lymphocytic leukemia cells","volume":"15","author":"McCaw","year":"2017","journal-title":"EBioMedicine"},{"key":"2025093003513335900_vkaf103-B12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1172\/JCI200519935","article-title":"Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts","volume":"115","author":"Zhuang","year":"2005","journal-title":"J Clin Invest"},{"key":"2025093003513335900_vkaf103-B13","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1038\/s41467-020-17179-4","article-title":"Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate","volume":"11","author":"Bibby","year":"2020","journal-title":"Nat Commun"},{"key":"2025093003513335900_vkaf103-B14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer Cell"},{"key":"2025093003513335900_vkaf103-B15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/toxins8030067","article-title":"Perfringolysin O Theta toxin as a tool to monitor the distribution and inhomogeneity of cholesterol in cellular membranes","volume":"8","author":"Maekawa","year":"2016","journal-title":"Toxins (Basel)"},{"key":"2025093003513335900_vkaf103-B16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/leu.2017.162","article-title":"PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"2025093003513335900_vkaf103-B17","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.4049\/jimmunol.2200199","article-title":"Enhanced IFN sensing by aggressive chronic lymphocytic leukemia cells","volume":"209","author":"Luo","year":"2022","journal-title":"J Immunol"},{"key":"2025093003513335900_vkaf103-B18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.2019003715","article-title":"Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"key":"2025093003513335900_vkaf103-B19","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/bioinformatics\/btm254","article-title":"GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor","volume":"23","author":"Davis","year":"2007","journal-title":"Bioinformatics"},{"key":"2025093003513335900_vkaf103-B20","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025093003513335900_vkaf103-B21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"2025093003513335900_vkaf103-B22","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/leu.2012.329","article-title":"PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia","volume":"27","author":"Spaner","year":"2013","journal-title":"Leukemia"},{"key":"2025093003513335900_vkaf103-B23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3324\/haematol.2022.281266","article-title":"PI3K inhibitors in CLL: where do we go from here?","volume":"108","author":"Sk\u00e5nland","year":"2023","journal-title":"Haematologica"},{"key":"2025093003513335900_vkaf103-B24","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/ni.3487","article-title":"Control of the innate immune response by the mevalonate pathway","volume":"17","author":"Akula","year":"2016","journal-title":"Nat Immunol"},{"key":"2025093003513335900_vkaf103-B25","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/leu.2016.356","article-title":"IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus","volume":"31","author":"Drennan","year":"2017","journal-title":"Leukemia"},{"key":"2025093003513335900_vkaf103-B26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2011-02-339911","article-title":"Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology","volume":"119","author":"Pello","year":"2012","journal-title":"Blood"},{"key":"2025093003513335900_vkaf103-B27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41392-022-00948-6","article-title":"c-Myc-driven glycolysis polarizes functional regulatory B cells that trigger pathogenic inflammatory responses","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2025093003513335900_vkaf103-B28","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.4049\/jimmunol.176.6.3830","article-title":"Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity","volume":"176","author":"Tomic","year":"2006","journal-title":"J Immunol"},{"key":"2025093003513335900_vkaf103-B29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41385-022-00504-z","article-title":"FoxO1 suppresses IL-10 producing B cell differentiation via negatively regulating Blimp-1 expression and contributes to allergic asthma progression","volume":"15","author":"Wang","year":"2022","journal-title":"Mucosal Immunol"},{"key":"2025093003513335900_vkaf103-B30","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.4049\/jimmunol.1300712","article-title":"The proto-oncogene c-myc regulates antibody secretion and Ig class switch recombination","volume":"190","author":"Fern\u00e1ndez","year":"2013","journal-title":"J Immunol"},{"key":"2025093003513335900_vkaf103-B31","doi-asserted-by":"crossref","first-page":"4186308","DOI":"10.1155\/2020\/4186308","article-title":"The Emerging Role of Rab5 in Membrane Receptor Trafficking and Signaling Pathways","volume":"2020","author":"Yuan","year":"2020","journal-title":"Biochem Res Int"},{"key":"2025093003513335900_vkaf103-B32","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1074\/jbc.M708069200","article-title":"3-phosphoinositide-dependent kinase 1 deficiency perturbs Toll-like receptor signaling events and actin cytoskeleton dynamics in dendritic cells","volume":"283","author":"Zaru","year":"2008","journal-title":"J Biol Chem"},{"key":"2025093003513335900_vkaf103-B33","doi-asserted-by":"crossref","first-page":"e27464","DOI":"10.1371\/journal.pone.0027464","article-title":"Regulation of interleukin-10 receptor ubiquitination and stability by beta-TrCP-containing ubiquitin E3 ligase","volume":"6","author":"Jiang","year":"2011","journal-title":"PLoS One"},{"key":"2025093003513335900_vkaf103-B34","article-title":"The association of dyslipidemia with CLL: a population-based study","volume":"109","author":"Mozessohn","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2025093003513335900_vkaf103-B35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/bjh.17733","article-title":"Statin use and survival in 16,098 patients with non-Hodgkin lymphoma or CLL treated in the rituximab era","volume":"195","author":"Br\u00e5nvall","year":"2021","journal-title":"Br J Haematol"},{"key":"2025093003513335900_vkaf103-B36","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/s41591-019-0597-x","article-title":"Avoidable flaws in observational analyses: an application to statins and cancer","volume":"25","author":"Dickerman","year":"2019","journal-title":"Nat Med"},{"key":"2025093003513335900_vkaf103-B37","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2119\/molmed.2011.00360","article-title":"Intraclonal complexity in CLL: fractions enriched in recently born\/divided and older\/quiescent cells","volume":"17","author":"Calissano","year":"2011","journal-title":"Mol Med"},{"key":"2025093003513335900_vkaf103-B38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"key":"2025093003513335900_vkaf103-B39","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70881","article-title":"Effect of statins in the watch and wait phase of CLL","author":"Spaner","year":"2025","journal-title":"Cancer Med"},{"key":"2025093003513335900_vkaf103-B40","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1161\/CIRCULATIONAHA.120.046542","article-title":"Dietary geranylgeranyl pyrophosphate counteracts the benefits of statin therapy in experimental pulmonary hypertension","volume":"143","author":"Zhu","year":"2021","journal-title":"Circulation"},{"key":"2025093003513335900_vkaf103-B41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2125.2011.03907.x","article-title":"What is a relevant statin concentration in cell experiments claiming pleiotropic effects?","volume":"72","author":"Bj\u00f6rkhem-Bergman","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"2025093003513335900_vkaf103-B42","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejmech.2014.08.037","article-title":"Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies","volume":"85","author":"Fong","year":"2014","journal-title":"Eur J Med Chem"},{"key":"2025093003513335900_vkaf103-B43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2020005734","article-title":"Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1","volume":"137","author":"Kohlhaas","year":"2021","journal-title":"Blood"},{"key":"2025093003513335900_vkaf103-B44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/10428194.2019.1675877","article-title":"The role of MYC in the transformation and aggressiveness of 'indolent' B-cell malignancies","volume":"61","author":"Filip","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2025093003513335900_vkaf103-B45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","volume":"19","author":"Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"2025093003513335900_vkaf103-B46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2020006765","article-title":"Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia","volume":"138","author":"Murali","year":"2021","journal-title":"Blood"},{"key":"2025093003513335900_vkaf103-B47","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ijc.22372","article-title":"c-MYC activation impairs the NF\u03baB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma","volume":"120","author":"Schlee","year":"2007","journal-title":"Int J Cancer"},{"key":"2025093003513335900_vkaf103-B48","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/emmm.201101045","article-title":"A statin-regulated microRNA represses human c-Myc expression and function","volume":"4","author":"Takwi","year":"2012","journal-title":"EMBO Mol Med"},{"key":"2025093003513335900_vkaf103-B49","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abc0653","article-title":"Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses","volume":"13","author":"Gorby","year":"2020","journal-title":"Sci Signal"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/9\/2453\/63419493\/vkaf103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/9\/2453\/63419493\/vkaf103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:51:49Z","timestamp":1759218709000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/214\/9\/2453\/8155361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,6,2]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jimmun\/vkaf103","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,6,2]]}}}